BackTable / MSK / Podcast / Transcript #74
Podcast Transcript: Diagnosis & Treatment of Tarlov Cysts
with Dr. Kieran Murphy
Attention radiologists: Were you trained to look for Tarlov cysts when reading spine MRI? In this episode of Backtable MSK, interventional neuroradiologist Dr. Kieran Murphy joins the studio to discuss the serious issue of chronic pain related to Tarlov cysts, a condition often overlooked in both diagnosis and treatment. Tarlov cysts, also known as perineural cysts, are fluid-filled sacs that form due to the dilation of the subarachnoid space around spinal nerve roots, most commonly at the base of the spine. You can read the full transcript below and listen to this episode here on BackTable.com.
Table of Contents
Diagnostic Differentiation and Interventional Techniques for Tarlov Cysts
CSF Leak vs. Tarlov Cyst
Hormone-Associated Immunologic Risks of Fibrin Use
Addressing Implicit Bias & Diagnostic Gaps
Practical Advice for Building Tarlov Cyst Management Programs
Radiation Safety in Interventional Practice: DNA Damage and DNA Halo
Personal and Institutional Efforts in Addressing Radiation Exposure
Listen While You Read
Stay Up To Date
Follow:
Subscribe:
Sign Up:
[Dr. Jacob Fleming]
Hello, everyone, welcome to the BackTable MSK Podcast. We have another special session here. We're on-site, BackTable HQ, in now sunny San Diego. We are here for the ASSR 2025 meeting, and I'm here with a special guest returning very quickly after his last appearance on BackTable, Dr. Kieran Murphy. Dr. Murphy, welcome back to the show.
[Dr. Murphy]
Thank you so much. It's always an honor to be asked to speak, so thanks.
[Dr. Fleming]
This is something you and I have been trying to do for some time.
[Dr. Murphy]
Right. Yes.
Tarlov Cysts: Clinical Significance and Diagnostic Challenges
[Dr. Fleming]
It's probably about a year and a half. It's time. The world is ready for the definitive discussion of Tarlov cysts. This is a really fascinating topic in that, as radiologists, especially neuroradiologists, are probably at the forefront for diagnosis of this entity, and yet we get very little, if nothing, in our training about what is the clinical meaning. What actually is this? Tell us, what are Tarlov cysts?
[Dr. Murphy]
These are dilatations of the dura over the distal nerve roots at usually S234. In about 20% of the people who have them, they're painful, but 80% of people will have pain from something else. It's really important to work out who is the appropriate patient, and systematically exclude everything else before you treat the cyst. They were initially described by Tarlov in McGill in Montreal based on pathologic dissections of cadavers in the anatomy lab in the 1920s, and he published a paper, I think, in 1934 about them. Then they were dismissed, largely, by bald white guys like me, as not significant.
There's gender bias in this. There's dogma in this. Humans are weird. There are things we decide, "That doesn't matter." We have phrases like, "Not uncommon." What does that mean? What is not uncommon? It's common or is it--? We do this to ourselves in medicine all the time, and we overlook things. A good example would be imaging of stroke that focuses on the carotid bifurcation. Why do we look there? It's because we do an endarterectomy or we stent it. We don't look at the rest of the pipe from the apex left ventricle to the MCA branches to look for atheroma.
We focus on certain areas because that's our food source. When we do a lumbar spine MRI, we look at the disc, we look at the end plates, we look at the cauda equina, we look at the nerve roots, and the dura. We don't look anterior to the sacrum, and we don't look at the facet joints much. We don't look for synovial cysts coming off the posterior aspect of the facet joints. We look where the money is, and we have to stop doing that. In particular, in women, these cysts have been overlooked, and for some reason, radiologists took to saying these are asymptomatic.
This would commonly show up in reports, and somehow this became urged by an urban legend with no basis in science because there's never been a paper saying they're asymptomatic. I've written a lot about this. I've written some very boring papers. I've seen close to 2,000 patients now. I've treated about 20% of them. They're not the easiest patients in the world to look after because many of them have had negative experiences with physicians dismissing them. They've often been through the whole path of gabapentin, Lyrica, oxycodone, and then the worst, fentanyl patches, which you can never get people off.
They've often lost their jobs, lost their families, lost their homes, become isolated, and then they get entrapped in this whole online world of misinformation about Tarlov cysts, where they think the be-all and end-all is to go to a handful of US surgeons for Tarlov cyst surgery. When I see them come back from that, usually they're worse. It's a combination of our behavior, their experience, the commoditization of Tarlov cysts by a handful of mercantile surgeons, and it creates a difficult environment to communicate with that patient openly. I've been looking after people with this for 20 years.
When Don Long, a brilliant chair of neurosurgery at Hopkins, asked me to look after the first few patients. It's not been easy, but it's been worthwhile, and about 70% of these people can be made better. I'm delighted you're interested in this. It's a good example of the fact that it takes about 20 years for things to catch on in medicine. What can I tell you? How can I help?
Diagnostic Differentiation and Interventional Techniques for Tarlov Cysts
[Dr. Fleming]
You covered so much there, and so much to unpack with the significance of the Tarlov cysts. A difficult population and often their imaging is read as essentially negative, and perhaps the only thing that's mentioned out of the ordinary is Tarlov cyst, so a lot of these patients somewhat naturally latch on to, "This has to be the cause for my symptoms." As you said, it is some of the time. Tell us about how you tease that out a patient who's come to you and said, "I have a Tarlov cyst?" How do you tease out, what are the symptoms? Is the cyst causing it? How do we go from there?
[Dr. Murphy]
First of all, I get all my patients - their GP has to send the referral, their family doctor. I have to get a formal referral from that person, not the person referring themselves. I practice now in Canada, in Toronto, where we have a socialized system. My salary doesn't change whether I treat 1 or 200. We get the referral, then I review their imaging, then I have a consultation with them. Reviewing outside imaging in itself is a pain because you've got to figure out how to read that CD or how to download that thing from Public Health or whatever. Then, we talk.
I divide the patients into those who have pain from something else and those who may have pain from their cystic dilatation of distal or caudal sacral nerve roots. I look for other causes of low back pain, radicular pain. There will be a handful of people who have a congenital anomaly. They will have some ligamentous laxity, and they will have perineural cysts all the way down. On sagittal T2, I'll look at the C-spine, T-spine, C of each little neuroforaminal has a light bulb in it, some dilated perineural cyst.
[Dr. Fleming]
Neurolactasia, yes.
[Dr. Murphy]
Then you know already, there's something more systemic going on here. Then I look in the sacrum for degenerative disease, for set joint disease in particular. Many of these people cannot sit. I look anterior to the sacrum for fibroids, ovarian masses. It's amazing how many have been missed, or piriformis syndrome, or ischial vine tuberosities, or irregularities, or spicules of bone or other things, and prior trauma to the sacrum, where somebody might have fallen out of a tree when they were a kid, but now at 52, they've got an abrupt angulation at S34 and they've got pain from that.
The funny things happen with that. Somebody goes on a Zempic, and previously they had a little cushion, and now the cushion is gone, and that fracture is painful. You have to go through step by step to figure these things out. In terms of the anatomy of the sacral abnormality, because it's usually S234, Tarlov cysts are a particular narrow-necked entity with minimal communication with the subarachnoid space around the distal caudal nerve roots. There are meningeal diverticula, which are wide-necked communications which are really form fruits of sacral agenesis or digenesis.
You'll have these big dilated distal, sacral, dural, CSF-filled sacs that directly communicate with the nerve roots around the distal spinal canal. Sometimes you'll see a lipoma of the phylum terminale going into them, and you do not treat those. They were built like this. It's the way that person is built. Their pain may be from something else. There will be people with erodent loss or Marfan's or Loeys-Dietz who have enormous duralectasias, and sadly, there is nothing you can do for them. That's a case of waiting for reincarnation. In those patients, sometimes I see, I'm thinking of two or three in particular.
Particularly one young lady who had tattoos everywhere, really quite terrifying to see, and she was the nicest, kindest person. She was more tattoos than surface area, almost, but when she lifted a heavy object, she would Valsalva. This would push fluid into her presacral dilatation, giving her transient intracranial hypotension. Then, it would recover over the next half hour or so. She eventually died. Some of these people will commit suicide because they have chronic, untreatable, unmanageable pain and no hope. The risk of suicide in this group overall is quite high.
A lot of these folks they have this underestimated, misunderstood, chronic pain at S234, in their pelvis, in their vaginas, in their perineums, down their legs. They've been told they're not symptomatic by orthopedic surgeons, spine surgeons, that this isn't a thing. They've been put on horrible drugs by spine guys who just want to put them on Lyrica and Gabapentin, which are cynical drugs because they do nothing for the underlying condition. They're anticonvulsants that were designed for epilepsy, that Park Davis figured out could be sold for other things even more. They're shit drugs. They're so over-prescribed.
They get depressed. If they're in some place where they don't have a good family doctor and they've no one to communicate and they're isolated, they will kill themselves. It's not uncommon. I hear this once or twice a year. You have to take these things seriously. They're existential for some patients. Now, the ones that I treat, I can define as the cause of the symptoms. They will be narrow-necked. Usually, they've eroded bone around them. The signal on T2 is going to be higher in the cyst than the adjacent subarachnoid space because it's not recessing. It's not moving. You've got static CSF. It'll be slightly brighter on T2.
The bone erosion is fascinating because you're talking about CSF pressure in a cyst and pulsating with each cardiac output, because the brain's a pump. This erodes cortical bone over time. You're talking about millimeters of water causing bone erosion. That's really unusual. Normally, you're talking about mercury and sphygmomanometers and that level of pressure, not millimeters of water. The bone erodes, I think, the distended dura around the cyst, is the cause of the pain because it's referred from the dural innervation of the cyst. Often, when I pass my needle through that dura, they reproduce their pain. That's really reassuring.
If I'm not sure, I will do nerve root blocks around the nerve that is compressed. Usually, this is S2. The S2 adjacent nerve that's compressed can be flattened and ribbon-like between the cyst and the adjacent bone. When you deflate the cyst and treat the cyst, you see that formerly ribbon-like nerve becomes plump again and slightly oval. The symptoms go away. As the cyst retracts and shrinks, that nerve will re-expand. I firmly believe that these patients, I treat them a bit like gardening. You don't finish your garden in one day. If you try and do everything at the one time, you can hurt people.
Our job is not to make people worse. I will stage things if I have to. Aspirate the cyst, put in half or one cc of 1% lidocaine to see if there's symptoms. If that works, then I use that two-needle technique that I described, which is really simple.
[Dr. Fleming]:
Yes. I wanted to hear you talk about it. I think this is one of the compelling things.
[Dr. Murphy]:
Yes. The first one or two patients I treated, I caused them more pain than anything else I've done. When you try and aspirate liquid out of a closed space, you can't. Then at two, three, in the morning, I just thought of how we get detergent out of a big detergent bottle. There's a vent. How we used to drink beer by putting two holes in the can. That's how I thought I'll put in two needles and take the stylet of both out. One goes deep, one is relatively superficial. Aspirate from the deep one, get an air fluid level. If the air fluid level stays over about three, four, five minutes, you know it's a narrow neck cyst that's not going to refill, and you can safely put Baxter to seal fibrin into it.
I add probably half a cc of 1% lidocaine up front just to decrease post-operative pain because the fibrin can cause some inflammation. Now, is this on-label or off-label? To discuss that. Baxter's fibrin has been used for years as a dural sealant for spine surgery. I think it's arguable. It's a bit gray. We do need a better dural sealant. All this work on CSF leaks tells us we need a better dural sealant. I've been fortunate enough to be asked to work on a better one that looks interesting. It works and it's safe. That's the technique. Two needles, one deep, one superficial, air fluid level, weight, then put in fibrin.
I put in about 80% of the volume of CSF that I aspirated because there will be some inflammatory reaction. How do I get the needles in? The lamina usually will have a defect in it from the chronic expansion of the cyst and the erosion of the bone. I find that defect and put the needles in through there. I find the place of most thinned lamina, and I just use conventional 18-gauge spinal needles, and I get them to go through that thinned lamina by spinning them at my fingertips. Very little pressure. Just spin them, and it will go through the lamina.
You put in one, they experience their typical pain. You put in the other, then you aspirate. That's all there is to it. What's the retreatment rate? About 20 to 30% after a few years. Because I don't move my job. I've only had two jobs. 10 years at Hopkins, 15 years in Toronto, I have a longitudinal follow-up on people. Over time, you see the cyst shrink and shrink and shrink and go away. These folks will let you know if they have recurrences or other things happen. That's all there is to it. It's pretty simple.
[Dr. Fleming]
Yes.
[Dr. Murphy]
It's just about patient selection.
CSF Leak vs. Tarlov Cyst
[Dr. Fleming]
Fantastic. You mentioned the somewhat related entity of CSF flow abnormalities. Obviously, this is a hot topic, especially within the neuroradiology community.
[Dr. Murphy]
Yes.
[Dr. Fleming]
Can you talk a little bit about how this relates to the broader emphasis towards improved diagnosis and treatment of CSF abnormalities?
[Dr. Murphy]
Follow the money, right? I actually think we have an ethical issue with over-treatment of people's headaches and it being turned into a cash cow by centers who are commercializing that. We need to be careful with that. There are more trial and assist patients out there looking for care than there are people with CSF leaks. Yet all the focus is on CSF leaks. Why is that? It's money. I've seen this once or twice before. Y90 is a good example. I think those institutions that are turning these patients into their product line and charging outrageous sums should be subject to some ethical oversight.
I think it's a problem. We have a big CSF leak program at Toronto Western Hospital. Richard Farb, my gifted colleague, is probably the father of all this. He doesn't go to many meetings, doesn't speak at many meetings, has trained most of the people doing this. He's a great guy. He's like, "I'm just going to do my work." He's really great at it. Mehran, the person we just recruited, trained with him and me, and he does it too. I see this energy to pursue every headache as a potential CSF leak. There are a lot of headaches in the world.
[Dr. Fleming]
Absolutely. Yes.
[Dr. Murphy]
There needs to be better patient selection.
[Dr. Fleming]
I agree with that. I trained in an institution that at the time had a very vigorous blood patching program. The neurologist who was there at the time was one of these experts in CSF hypotension. A lot of the patients that you've alluded to multiple times now, these patients have been put through it and bounced around.
[Dr. Murphy]
Yes, yes.
[Dr. Fleming]
It's a difficult situation where you have a patient who has been to tertiary, quaternary care facilities. They're saying they're hanging their hope on this as a diagnosis. I have to agree with you, though. I think that sometimes what can be a nebulous diagnosis is made de facto, that has to be the diagnosis. That's a difficult thing, I think, about CSF leaks and Tarlov cysts in particular. Sometimes patients are--
[Dr. Murphy]
Yes, to separate out the Tarlov cysts, I think that we can define with a dermatome distribution what is causing the problem. When you start to get into this whole weird world of cranial cervical instability and chronic headaches, and imaging negative CSF leaks and headaches being so common, and so many reasons for headaches. I don't mean to dismiss the suffering of people with these problems or any of the other functional abnormalities that people suffer from. These are terrible complaints to have. They are terrible diseases to have. The commercialization of them is an ethical issue. We've had this before in medicine. It's not uncommon.
If you look at the great bad procedures in medicine over the years. I would include typhoplasty in that. Here's a procedure with very little benefit over conventional vertebroplasty. The destruction of functional tubercular and the overselling of an expensive technology, and the minimal height restoration it achieves by comparison to a simpler technology, where the same restoration of height can be achieved by high-viscosity cements. Ultimately, a lot of these things are about us, not the patient. The patient cares about the implant. I care about my aortic valve replacement more than I do the surgery that happened six years ago. I live with that valve.
People will live with their PMMA in their vertebrae. Why are we still using PMMA? Dentists stopped using that 30 years ago. I think we have to question everything we do systematically, rigorously, look for our unconscious or implicit biases, and challenge ourselves to do better. We exist at the apex of Maslow's hierarchy of needs in medicine. If we're doing things like this here, what's happening in the rest of the world? How transferable are the things that we are doing to other medical cultures? South of the U.S. border, south of the Mediterranean, east of the Alps.
I constantly look at what we do with a certain level of functional circumspection to make sure that I'm trying to do better. I worry about this whole headache thing. I've sat in the back of those meetings. One person was asked about how many allergic reactions they'd seen to fibrin glue. This person said, "Well, I've-- Oh, I've injected, probably, Fibrin 2000 times." I'm thinking that means you don't have a target. You don't know where you're putting it. You don't have a specific location to put that fibrin.
If you're putting fibrin at every level, whether it's a perineural cyst in somebody's T-spine, you don't know what you're doing. As neurodivergentalists, if I'm off by a millimeter, something goes haywire. I think we have to look at the technique, we have to look at the implant, we have to look at the logic, we have to look at the culture of what's going on, and get more specific and get more focused. It's always about the implant. It's always about the mechanism of action.
[Dr. Fleming]
That's so thought-provoking, everything that you just said. It makes me think about, we talked about, the commercial aspect. How does that inform what has a future for improvement, for treatment for Tarlov cysts?
[Dr. Murphy]
We need a better-- First of all, I'm fascinated by CSF. We don't think about liquids. We don't think about liquids much. I'm fascinated by synovium. I know that sounds bizarre. Do you think the synovial fluid at occipital C1 is the same as the synovial fluid in your ankle?
[Dr. Fleming]
No, probably not.
[Dr. Murphy]: No, it wouldn't be. If you've got a car, you're going to have gearbox oil in the gearbox, you're going to have axle stuff on the axle, you're going to have different fluids lubricating the engine. When we look at Synovest, why is it the same everywhere? Should we not actually study the synovium, the synovial fluid in different locations, and see what is specific to that? When you think about a Tarlov cyst, why is the CSF like that, and what is it doing, and what can it tolerate being in there with it? Now, sadly, nerves only like CSF. If there's a nerve in that cyst or in the wall of that cyst and I put fibrin in there, it's going to get pissed off.
I need to come up with a fibrin sealant, a dural sealant, that does not cause a neuritis of some kind by being a foreign body. When people are treating CSF leaks, they need to have a material that does that as well. Adhesives to dura shuts the hole because fibrin's not very adhesive, and actually solves the problem, and be really specific on what they're doing.
Hormone-Associated Immunologic Risks of Fibrin Use
[Dr. Fleming]
Right. So much to think about. One thing I did want to talk about some, which you alluded to a moment ago, is the very real phenomenon of the development of allergy to fibrin sealant and something I've seen that's fairly common. Tell us a little bit more about that.
[Dr. Murphy]
I've only ever seen it once, and this lady developed hives and a rash, and we kept her overnight and gave her some dexamethasone, and it went away. I think it probably indicates overuse, overexposure, repeated treatment, the thrombin issue. There are people who are allergenic. They're allergenic to everything. I had fun a few years ago, I wrote a great paper on severe allergic reactions to iodinated contrast. 80% of severe allergic reactions to iodinated contrast occur in women of reproductive age. Now, who gets allergies to fibrin? Women of reproductive age, right? Because they're the same group that gets the chronic headaches and everything else.
Why does this happen, and why didn't we know this happens? There are two questions. Why are the most common allergic reactions to contrast in women post-menarche and pre-menopause, or on hormone replacement therapy, or undergoing gender transition, or biological? I want to get the right language there. Why didn't we know it? We did a meta-analysis of the literature on contrast reactions, we looked at our own experience in Toronto. We're able to clearly identify that 80% of the severe allergic reactions are related to women with elevated levels of estrogen for physiological purposes in their system, or for HRT or other things.
This is known in what I call the wheezes and sneezes literature, in the allergy immunology literature. I contacted my friends who focus on that world, and they go, "Yes, we see it in reactive airways disease. We see it in drug allergies. It's well understood." Again, why didn't radiology know that? Because we're lame about this stuff. We're like, "Jesus, we just need to do better." This is a huge deal. When you're on call as a resident and they say, "There's a lady with a history of allergy and she reacted to iodine and she needs more contrast and she's 35 and can we just go ahead and do it? She'll be okay." The answer is no.
Now, if she's 12 or if she's 65 and post-menopausal, probably, but that should be taught. We published this in radiology, and one of my brilliant fellows, Jesse Klostranec, worked out the mechanism by which this occurs. He's really gifted. That's the fun stuff we should look at. If people are having allergic reactions to fibrin from CSF overuse because they don't have a target when they're trying to find the leak, it's probably because there's an element of allergenicity in that patient population because of their levels of estrogen.
Addressing Implicit Bias & Diagnostic Gaps
[Dr. Fleming]
Very interesting. It relates back to one of the core themes in this topic of the implicit bias involved in the underlying population. You should talk a little bit about that.
[Dr. Murphy]
As a white-bald male, I don't have a right to. My daughter teaches me a lot, and my wife and her friends are all women physicians who work in predominantly male hospitals and come across concrete ceilings all the time. I wrote a chapter in that book about that. Looking at why there aren't more women inventors. Humans are flawed and we're fragile, and we make mistakes, and we have to be conscious of our errors and try and do better. I don't get it right most days. Some days, once or twice a year, I might get it right. I think it's important to have insight into the basis of our judgment.
[Dr. Fleming]
Yes. I agree, and it can be difficult, especially in our position. Often we're being referred patients who've been seen by a lot of other physicians. For some reason, and I call it the black pearl, it's that, "Oh, this patient has fibromyalgia." They've been told that. We take whatever that proclamation is as the truth. We continue running with it. We have to have a discerning eye and think, "Is that really true? Is that the source of the problems?" I feel that these patients often end up in that situation, "Oh, yes, they have fibromyalgia. They have a Tarlov cyst, and it all relates to that." They need someone with the diagnostic acumen and ability to say, "Does this make sense?"
[Dr. Murphy]
There's empathy and telepathy almost involved in that. There are harmonic frequencies that we can communicate with patients on, sometimes intuitively. Does that make sense? I understand this person.
[Dr. Fleming]
Right.
[Dr. Murphy]
I know they're frightened. I've got to go make sure they understand I am committed to making them better. Now, this is the key to the placebo effect.
[Dr. Fleming]
Right.
[Dr. Murphy]
I'm a huge fan of the placebo effect. A big fan. I think a lot of what I achieve is thanks to that. We shouldn't underestimate it. I think, to be honest, long COVID teaches us a lot about how people with fibromyalgia are treated, and it's changed their awareness that it's a thing. Again, predominantly women. The other thing is there's a lot to be said for like, gout and a big red toe. You can point to it and go, "That's gout."
[Dr. Fleming]
Yes, right.
[Dr. Murphy]
Thank God, it's a sign. I have psoriatic ankylosing spondylitis, and I've had it since 1999. I've been on prednisone and methotrexate and all these things. I got disseminated histoplasmosis after. I was really sick after one of the grumbly mabs. I, first of all, didn't know what was wrong with me. I just thought I was tired. Then I got dactylitis in my left hand. Thank God I did, because you could point to it and show it's abnormal. There's a lot to be said for having a visible clinical sign. Now, with these ladies with Tarlov cysts, if you dismiss the cyst as the cause of the problem, then they have no problem. Then they get bucketed with the fibromyalgias and everything else.
[Dr. Fleming]
Right.
[Dr. Murphy]
It's important to identify that those things can be sometimes symptomatic. Like I stated in the report, not necessarily say "Do cause," but "Can cause," radiculopathy and symptoms. Also, when people read that MRI, they look at the uterus. 60-year-old women shouldn't have huge fibroids. Plus, they can compress the ilial lumbar plexus asymmetrically and cause radiculopathy, et cetera. Then, if I may go back to this topic of things we do badly, endometriosis. If men had endometriosis, we'd have it sorted by now. I always think of Viagra getting approved within weeks in Japan, and then oral contraceptives not getting approved for years.
Endometriosis is one of those diseases that we do a terrible job with. Those women can get cyclical sciatica with endometriosis on the lumbar sacral plexus. This persists after menopause. That can cause radiculopathy. I've had women almost break into tears when I've asked them if their sciatica was cyclical, because men don't ask. Below the belly button, we're not going to discuss that. These are all part of that. We weren't just aware of things that were related to Tarlov cysts.
[Dr. Fleming]
You mentioned this in your recent conversation with Aaron about the need for better imaging for endometriosis. This is a really interesting topic. I remember in med school, we had to put together a proposal, a theoretical proposal for the administration about, "Here's how we should treat this problem." We chose endometriosis. I would say my understanding from that very perfunctory stage as a med student through radiology residency, now as an attending, my understanding of endometrial imaging hasn't changed too much because there's not much focus on it.
[Dr. Murphy]
No. We have dodgy MRI. You can't use a radioisotope because it'd be radiating endometrial tissue, which we've had. We need some biomarker for that. The other thing that we're not good at is polycystic ovarian syndrome, and young women really suffer with that. Yes, we just need to try harder and look at what we do badly. Sometimes I think we still essentially do phrenology. We're not that far from it, and we need to move beyond that geographic anatomic abnormality and start treating tissue that is functionally abnormal rather than visibly abnormal.
If you could imagine oriflablation of PET-positive head and neck cancer prior to it becoming abnormal, visibly on MRI. That kind of thing. That would be fun with a PET detector on the tip of your needle. A fellow called Rich Wall developed that years ago. There are times when we can start new procedures because the belief system catches up with the available technology.
[Dr. Fleming]
Sure.
[Dr. Murphy]
That's about 20 years. If you look at the adoption of technology, it takes so long for physicians to change their behavior and to see what's in front of them.
Practical Advice for Building Tarlov Cyst Management Programs
[Dr. Fleming]
On that note, we like to talk sometimes about practice development, and I think this does go hand in hand. We've been talking about patient populations very much in need, talking about the Tarlov cysts. You, of course, your entire career has basically run in parallel with the development of the techniques to actually treat these patients, and you've had to figure out as you go. For those who are starting out and looking to start a Tarlov cyst practice, how would you recommend getting started? It could be pretty overwhelming.
[Dr. Murphy]
Yes, slowly. I think you have to have some-- It depends on the culture you're in. If you're in a supportive culture-- My first job out of fellowship was pretty shit. I had been a resident there, then I left, did a fellowship, and came back as the head of neuroradiology, and the people who had trained me as a resident were really mad at me, and so there was zero support. It was awful. One of the most difficult years of my life. That's not the context in which you do new things. If you got, in your first job, you walk into an established department, where they would--
When I arrived at Hopkins, they'd seen neurointervention. When you're out of fellowship, I've set up interventional neuro at Hopkins on my own, but they'd seen it for 10 years, and the techs and nurses had seen it. There was a warm and embracing culture that allowed me to do things that were more risky, and my skills also improved over time. Then you can stretch. It depends on the context in which you practice. I think that's so important. If you're starting to look at Tarlov cysts, then orthopedic spine, neurospine, will want nothing to do with it, unless there are donor dollars involved, in which case, they'll be really interested.
I think the key group to work with would be the laparoscopic, endoscopic, OBGYN faculty. I have a fabulous colleague, Nustelio Lemos, that I work with, and also two pain physicians, Anush Bhatia and Philip Peng. Collectively, we can work through things together. They would treat everything else, and then I would treat the Tarlov cyst. If you have that culture of risk tolerance and confidence and comfort, then you can push. If you're on your own, in a hospital that is judgmental, then you shouldn't do this.
[Dr. Fleming]
That's great advice, and something that, as a new attending, I'm thinking about a lot, in terms of you have to have a balance between earning the trust of your staff, of your patients, of your community, versus expanding into things that you know can work, but you have that eye of scrutiny.
[Dr. Murphy]
Yes, you can always do more. You can never do less.
[Dr. Fleming]
Right.
[Dr. Murphy]
Right. It's like the last coil when you're quitting an aneurysm. I want to get rid of the last coil. It's always the last coil that gets you into trouble. It's like the third reviewer on the ground. It's always that guy. You can always do more, you can never do less. Patients will let you have them come back and do more, but if you have a bad outcome, then that's not acceptable. If you get cement in the epidural space or cement in the neuroforamen and you didn't stop, that will accumulate and cause you harm, and them harm, but also it'll bother you.
[Dr. Fleming]
Oh, absolutely. More than perhaps anybody.
[Dr. Murphy]
Except the sufferer of the problems. Yes.
Radiation Safety in Interventional Practice: DNA Damage and DNA Halo
[Dr. Fleming]
Speaking of doing more. I think this is probably a good segue into another thing you mentioned briefly in your conversation with Aaron is this DNA Halo. This is a fascinating topic, and I think really important, as you mentioned in that discussion. Ironically, in radiology, we don't seem to have the same focus on radiation safety as maybe in other fields like interventional cardiology, and we can sometimes be a bit cavalier about it. Tell us about the experience with DNA Halo, the insights that led to that, and where does this fit in for us?
[Dr. Murphy]
I have a cataract in my left eye. A lot of my friends have cataracts or other health issues. There are papers of 32 Japanese interventional cardiologists with left-sided brain tumors, that kind of thing. Famous interventional vascular surgeons, like Ted Dietrich, dying of both carotid stenosis and brain tumors from radiation. Often, radiology stupidly follows cardiology, and cardiology is clearly leading here with groups like Bob Foster and Rampart and radiation dose reduction and education, and awareness. There's a great TV show on PBS called Scattered Denial about occupational radiation detects nurses, physicians, and cardiac angiographers.
I think because of the long indwelling or time for tumors to develop or issues to develop after radiation exposure, we're probably not yet in the time frame where our colleagues begin to manifest the injuries they have sustained. We seem to have forgotten that the original founders of radiology lost toes and fingers and eyes and noses from standing in the X-ray beam. This is an occupational health issue. This needs to be something that we realize the hospital has a responsibility for, not us. Now, sadly, we often don't work for the hospital. The techs and nurses do, but we have occupational radiation exposure, just like a nuclear power station, just like a young officer in a submarine.
Our radiation exposure needs to be a problem for the hospital, and it be something that hospitals step up and take seriously. Our societies have fallen behind in this. They continue to talk about lead and the inverse square law and stuff like that. They need to just get their stuff together. I spent a long time studying the mechanism of action. I'll keep using that word, the mechanism of action of radiation injury. It's an oxidative injury of DNA, and antioxidants can block that. How this came about for me was, I was bothered by this. I was getting lots of radiation, and I came home from work, and my mother-in-law had a list of medications not to take prior to radiation therapy for her breast cancer.
They were all antioxidants. I look at this going like, "Jesus, if a gray of radiation to your axilla can be interfered with by vitamin C and some other antioxidants taken orally, what would that do for millisieverts?" My son, Ronan, and the dog Cora and I went for a walk, and the dog met another dog, and they were playing together. The owner of the other dog asked me, "What do you do?" I started talking about antioxidants, and Ivan D'Souza, the man's name I later found out, said, "I make antioxidants." It's like, "Whoa, shit." I did a bunch of experiments on myself and then two of my friends, Joe Barfitt and Dave Nicholas, got involved.
We would meet around 6 in the morning, we would draw our blood, we made a phantom, we would CT the blood, and then we would measure breaks with gamma H2AX and p53. Then we started to take Ivan's antioxidants and felt great, but it made us hypertensive, so we realized that was bad. Then I developed a formulation, did a prospective randomized study in humans having technetium MDP bone scans, and then that worked, 90% reduction in DNA breaks. Then, again, accidental conversation. Many of these things happen by accident, just from conversations. I met a mitochondrial disorders neurologist who was able to guide me on perfecting the formulation to protect mitochondria. Mitochondrial DNA is purely maternal. That is so cool.
[Dr. Fleming]
Yes, I've always found that really interesting.
[Dr. Murphy]
Yes. Why? Protecting that is important because it's 10 times more sensitive to radiation than nuclear DNA, and it could be transmitted across generations. Women interventionalists. Get the right word. Biologically female-- Biologically-- I think, that's the right phrase, right? Biologically female interventionalists.
[Dr. Fleming]
I think so, yes.
[Dr. Murphy]
It's important to be sensitive to that. Could potentially transmit mutations in mitochondrial DNA across generations. No one's even talking about that.
[Dr. Fleming]
No, I've never heard that talked about.
[Dr. Murphy]
Then the other thing is, should we be screened for mutations that would impair our ability to repair DNA damage prior to choosing our fellowship? Say, if you got a Smith syndrome, or you're BRCA1 or 2, or you're Askinazi, and you've inherited some odd DNA repair apparatus abnormality, or you've got hereditary telangiectasia. One of the other things that is a p53 mutation, that's 50% of the cancer risks come from p53 mutations, then you shouldn't be an INR or IR, or interventional cardiologist. You should do ultrasound-guided biopsies. We should know that, and we don't do that. It's sloppy, and we just need to do better.
Those are conversations that are not happening, because people are so focused on the rock, and billing, and money, and it's stupid. Those things are short-term goals, not long-term things for our safety, security, sanity, and our careers.
[Dr. Fleming]
A great point. Another short-term goal, that started you on this path, is the badge reading. Make sure you're turning your badge.
[Dr. Murphy]
Oh, most of us don't wear our badges. There are guys whose badge levels go up, but they just move to a different state, because badge levels are not tracked nationally, only statewide. Yes, that's insane.
Personal and Institutional Efforts in Addressing Radiation Exposure
[Dr. Fleming]
How do you see us as interventionalists? What are some immediate steps we can take? As you said, this really should be an institutional effort, but on an individual level, what are the types of things that we can do? Is DNA Halo something that you think we should be--?
[Dr. Murphy]
I think we need to look at our lead. Oh, the other fun thing we did, one of the most fun projects. I have a lot of students that I work with, and our job is to show them that medicine is fun, medicine is a liberal art. We swabbed the surface of the lead in all our hospitals, looking for free lead on the surface. We found 63% of the lead aprons have free lead dust on the surface. There's no safe level for lead in your system. Now, when I looked at the literature, I was bummed. I wanted to measure lead levels from people's hair, and somebody had already done it, and it's abnormal. We're ingesting this lead dust.
[Dr. Fleming]
Hmm.
[Dr. Murphy]
Yes. Again, we should know this. Why don't we know this? We have to try harder. We want to wear the best lead we can. We want to have the best lead shields we can. We want to have the best lead table-side skirts, one of those things that we can. We want to use those bunkers as much as possible. If you look at the Rampart folks, they've made trans-radial access to the heart lead-free, because their bunker is so good. That's a $200,000, $300,000 investment. Hospitals would have to buy that. They're going to say, "Oh, the budgets--" What they're really saying is, "You could get radiated. That's okay." It's not okay. We need to make a bigger fuss about this.
When our older machinery is radiating people, that's radiating us. Our nurses are putting their heads right beside the I.I. when they talk to the patient. Our techs are moving around, positioning things. There's ample literature to show that there's no safe level and that individuals vary in their ability to repair the damage. These are occupational, institutional responsibilities, and we need to make that clear to the institutions we work in.
[Dr. Fleming]
Absolutely. I couldn't agree more. I think you've raised a lot of really interesting things when you think about it as a field in terms of DNA mutations. Is that something that we should be checking for in potential people who are going to be spending their entire life next to a C-arm?
[Dr. Murphy]
Right. There's fun stuff, too, looking at mutations in the DNA. We've noticed this in the work that we did. Most complex research I've ever done. We were able to show that more experienced or older interventionalists have more DNA repair ability, more rapid repair, because they're used to-- |They've up-regulated the repair apparatus. Whereas younger faculty don't. A ton of papers in the cardiology literature show that folks with mutations have more cancer. Those papers exist, and they're in the peer-reviewed literature.
[Dr. Fleming]
It's all food for thought. I'm always glad to discuss with you. My mind is always open to new topics, and thank you so much for spending the time, especially to talk about this mystifying topic of Tarlov cysts.
[Dr. Murphy]
One thing briefly. In about 20 minutes, I'm going to meet Hal Koons of the Koonswire, who lives here. He hasn't worked for probably 10-15 years because of radiation-induced injury. He did a lot of gastric interventions, cataracts, radiation fibrosis in his hands from that. He's a great teacher. Then this afternoon I'm going to meet a bunch of guys from the US submarine fleet who are friends of mine, practical jokers. Pete Neal, who would wear the bins and could tell the difference between this submarine and that submarine based on the sound of the propellers. Those guys got a shedload of radiation. They would actually sleep on the missiles. Yes. There's no mystery here. There's tons of data.
[Dr. Fleming]
Absolutely. Any last words you'd like to share?
[Dr. Murphy]
No, I'm just really grateful for asking me to rabbit on about these things. It's always honestly a privilege to get asked to. Most people don't get to be heard. It's really important that we are inclusive of the voices we listen to.
[Dr. Fleming]
Great, and thanks for being one of those voices for us on BackTable, and I look forward to having you back.
Podcast Contributors
Cite This Podcast
BackTable, LLC (Producer). (2025, April 8). Ep. 74 – Diagnosis & Treatment of Tarlov Cysts [Audio podcast]. Retrieved from https://www.backtable.com
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
















